London: A June 2024 literature review, published in the Lancet Neurology, by Sisodya and colleagues revealed that climate change has the potential to intensify multiple sclerosis (MS) symptoms. The collated evidence aligns with GlobalData’s MS epidemiology and market forecast, which anticipates an uptick in the prevalence and disease severity of MS. The rise of a more severe MS population will drive the growth of the market over the next decade as the need for newer, more effective approaches to treatment arises, according to GlobalData.

The main treatments for MS focus on slowing the disease’s progression and are disease-modifying therapies (DMTs). According to GlobalData’s forecast on the multiple sclerosis market size, it is expected that sales for MS DMTs will grow to $30.1 billion by 2030, at a compound annual growth rate (CAGR) of 4.7 per cent during 2020 -30.

Jos Opdenakker, Pharma Analyst, GlobalData, commented, “Climate change-related exacerbations of MS will necessitate the development of novel, more effective DMTs as disease flare-ups become more frequent with fluctuating temperatures.”

GlobalData’s Pharma Intelligence Centre database reveals that there are two ongoing Phase III clinical trials in which new treatments are being actively compared to DMTs currently on the market. The trials are evaluating Novartis’s remibrutinib in the REMODEL-1 trial and Genentech’s fenebrutinib in the FENhance trial. Both trials are global clinical trials that aim to compare the efficacy and safety of both treatments against the current standard of care, Sanofi’s Aubagio (teriflunomide) in patients with relapsing MS.

Opdenakker continued, “These trials signify pharmaceutical companies’ interest in developing more effective DMTs, as the severity of MS symptoms is getting magnified due to climate change, a potential driver of growth in the MS market.”

Evidence suggests that health effects are even more likely to occur in cities that are better equipped to deal with extreme temperatures, emphasising the urgent need for research and policy development. With that being said, while research is being conducted and new health policies are under development, more effective DMTs have the potential to occupy the interlude as the main line of defense for MS patients against climate change.

Opdenakker concluded, “The review by Sisodya and colleagues calls for prospective, systematic, and disease-focused models of how climate change will affect the central nervous system. However, these will have to be coupled with new, more effective therapeutic interventions in order to form an all-encompassing, coherent strategy for managing MS in line with climate change.”

  • Published On Jun 7, 2024 at 12:53 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App